Nutlin-3

For research use only. Not for use in humans.

製品コードS1061

Nutlin-3化学構造

CAS No. 890090-75-2

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 32700
JPY 20200
JPY 30200
JPY 63400
JPY 163000
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

文献中Selleckの製品使用例(67)

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SMMC-7721  M1HleWZ2dmO2aX;uJGF{e2G7 MoPtNVAh|ryP MkPmN|YhcA>? MUHEUXNQ NV:1UHp7\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? NYrOW2NNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPFY{OTJpPkK0Nlg3OzF{PD;hQi=>
HuH-7 NHHZcllCeG:ydH;zbZMhSXO|YYm= MlrLNlAh|ryP MWO0PEBp NYnsfXRyTE2VTx?= MVLpcoR2[2W|IHHwc5B1d3Orcx?= M1rJNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki2N|EzLz5{NEK4OlMyOjxxYU6=
SMMC-7721  NXLybZFbSXCxcITvd4l{KEG|c3H5 MYGyNEDPxE1? MmHSOFghcA>? MX\EUXNQ NFTr[FFqdmS3Y3XzJIFxd3C2b4Ppdy=> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NkOxNkc,OjR{OE[zNVI9N2F-
HuH-7 NIrLVoJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV;YSWdIOS5{NT2yNEDPxE1? NF3iPVYzPC92OD:3NkBp NEDXN2tFVVOR MoDPbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NkOxNkc,OjR{OE[zNVI9N2F-
SMMC-7721  MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3\PNlEvOjVvMkCg{txO NFfoRVMzPC92OD:3NkBp NY\F[Xc5TE2VTx?= MlrabY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NHnreIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK4OlMyOid-MkSyPFY{OTJ:L3G+
RKO MkPDSpVv[3Srb36gRZN{[Xl? MlTQNlAh|ryP MWmyOEBp MlvXbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MkLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|Nk[wNFcoRjJ2M{[2NFA4RC:jPh?=
U2OS  MnvCSpVv[3Srb36gRZN{[Xl? MljiNlAh|ryP NIXqZoEzPCCq Mnq1bY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN4NkCwO{c,OjR|Nk[wNFc9N2F-
RKO NXy4bJJ6TnWwY4Tpc44hSXO|YYm= NIK2eWIzOCEQvF2= MlS2NlQhcA>? MnzDbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? M{XYbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{[2NFA4Lz5{NEO2OlAxPzxxYU6=
U2OS  MnXsSpVv[3Srb36gRZN{[Xl? NUXYfHlnOjBizszN MYKyOEBp M{L2Wolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? M2PsV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{[2NFA4Lz5{NEO2OlAxPzxxYU6=
MOLM NUK0UGJKTnWwY4Tpc44hSXO|YYm= MkL5NVAh|ryP NVryPWtjOjRiaB?= M4DDbpVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= NWT4e|g5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|M2PjJpPkK0OFc{PTZ{PD;hQi=>
OCI NWTxU5lpTnWwY4Tpc44hSXO|YYm= M1XqXFExKM7:TR?= Mo[wNlQhcA>? MUj1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? M4T0W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEezOVYzLz5{NES3N|U3OjxxYU6=
BeWo NHvQRo1CeG:ydH;zbZMhSXO|YYm= NX3hTlBMOzBiwsXN NVTXN3J5OjRiaB?= M3XxXolv[3KnYYPld{BieG:ydH;zbZM> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7OEG1OEc,OjR2OUixOVQ9N2F-
BeWo NV7YdpI3TnWwY4Tpc44hSXO|YYm= M2j1XVMxKML3TR?= NEn2fHMzPCCq NGf2PVNqdmO{ZXHz[ZMheDV|LDDN[I0zNCCyMkGgZY5lKFC3bXGgZZQhfGinIIDyc5RmcW5ibHX2[Yw> NUHjeVdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVgyPTRpPkK0OFk5OTV2PD;hQi=>
MOML13 NGjTbJRHfW6ldHnvckBCe3OjeR?= NGDNOJcyOM7:TR?= MkToNk81KGh? M3PLcIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz MnW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NUm3OFkoRjJ2NkW5O|Q6RC:jPh?=
AML3 NYfKZodGTnWwY4Tpc44hSXO|YYm= M4nUbVEx|ryP M3m2eFIwPCCq NXvCNVFkcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NUm3OFkoRjJ2NkW5O|Q6RC:jPh?=
AML2 MUXGeY5kfGmxbjDBd5NigQ>? MVKxNO69VQ>? M17QRlIwPCCq NITBRnhqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NYHKWmFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVk4PDlpPkK0OlU6PzR7PD;hQi=>
MOML13 M4\0OGFxd3C2b4Ppd{BCe3OjeR?= MXqyM|ExKM7:TR?= NWS5[llrOjRxNEigbC=> NIPYTmVqdmS3Y3XzJIFxd3C2b4Ppdy=> M4\GPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW5O|Q6Lz5{NE[1PVc1QTxxYU6=
AML2 NXjWTHZLSXCxcITvd4l{KEG|c3H5 MVmyM|ExKM7:TR?= MXWyOE81QCCq M17KTIlv\HWlZYOgZZBweHSxc3nz NWjiV4V6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVk4PDlpPkK0OlU6PzR7PD;hQi=>
U2OS  NXXIcXUyTnWwY4Tpc44hSXO|YYm= MnzGNlAh|ryP M1H0bFI1KGh? M2TqN4lv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe= NVfBTWN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlczPTlpPkK0PFY4OjV7PD;hQi=>
Hep3B NXvqWW9VSXCxcITvd4l{KEG|c3H5 M2\6PIlv\HWlZYOgZZBweHSxc3nz NEHkfno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
Huh-7 NXLDSnVtSXCxcITvd4l{KEG|c3H5 MWHpcoR2[2W|IHHwc5B1d3Orcx?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NEiwPUc,OjR6OES4NFk9N2F-
SMMC7721 NHvsUWdCeG:ydH;zbZMhSXO|YYm= Mo\ibY5lfWOnczDhdI9xfG:|aYO= NXu0OYlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
HepG2 NEDiZ3lCeG:ydH;zbZMhSXO|YYm= MlvpbY5lfWOnczDhdI9xfG:|aYO= M2DYTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi0PFA6Lz5{NEi4OFgxQTxxYU6=
Hep3B NWrVWlN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rISVczKGh? NWm5e|Q3TE2VTx?= NV3xVHJTUUN3ME2yNE4yQCEEsTCxMlg1KM7:TR?= NEnrbIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
Huh-7 NV7jfJJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[3NkBp NH:1RY5FVVOR M1\GWmlEPTB;M{OuPVYhyrFiMz65JO69VQ>? MlG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OES4NFkoRjJ2OEi0PFA6RC:jPh?=
SMMC7721/Ac MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW3NkBp NIfaOZJFVVOR M3e1[mlEPTB;NUWuNlEhyrFiNT6wN{DPxE1? M4rFTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi0PFA6Lz5{NEi4OFgxQTxxYU6=
SMMC7721 NI\J[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjWO|IhcA>? MorESG1UVw>? MkLHTWM2OD1|MT6yPEDDuSB2LkKg{txO MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NEiwPUc,OjR6OES4NFk9N2F-
HepG2/As MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULiPZVyPzJiaB?= NHLJbolFVVOR NFqwN5JKSzVyPU[4MlE{KMLzIEmuOkDPxE1? NInEe|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
HepG2 NFGyTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X3dlczKGh? NEPEfItFVVOR MnTyTWM2OD1|NT64OkDDuSB{Lkmg{txO NIDKZo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
MOLM-13 MYDGeY5kfGmxbjDBd5NigQ>? NFT3NWw3yqEQvF2= MnzNOkBp NV3vR5BxTE2VTx?= NWHsRVBS\W6qYX7j[ZMhfGinIHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhUDKEIHHu[EBp\WG2IIPoc4NsKHC{b4TlbY5{KEi|cEK3JIFv\CCKc4C5NC=> NEm4coM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OVA5Oid-MkS4PFUxQDJ:L3G+
MOLM-13 MmPUSpVv[3Srb36gRZN{[Xl? MlflOuKh|ryP M1HBflAuQCCq NF;RTHNFVVOR Mn\nbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicEWzMEBOTE1{LDDwNlEh[W6mIHHj[ZR6dGG2ZXSgdFU{ Mlu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEWwPFIoRjJ2OEi1NFgzRC:jPh?=
115 MmK0SpVv[3Srb36gRZN{[Xl? MVm1JO69VQ>? M2fvVFQ5KGh? M{HEcGROW09? NH7rTnNqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NUnwU3JsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
A498 NETOT25HfW6ldHnvckBCe3OjeR?= MXu1JO69VQ>? M1PQRVQ5KGh? M121d2ROW09? MVvpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NUjMOmV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
Caki-2 NFjQbWpHfW6ldHnvckBCe3OjeR?= MXG1JO69VQ>? MXm0PEBp Mn33SG1UVw>? NHTmZVZqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
ACHN NY\5UYd1TnWwY4Tpc44hSXO|YYm= M1HXVlUh|ryP NWPzWFU5PDhiaB?= NG\YNWRFVVOR NV7GeFU{cW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NU[2UpBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
115 M3Hremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nXbFUh|ryP NIK0V|Y1QCCq MkG3SG1UVw>? Mm[5bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NIjmcII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
A498 NXTxbG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvyOUDPxE1? MoL0OFghcA>? MnzqSG1UVw>? NYnn[JlVcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh M1Gyb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
Caki-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWK1JO69VQ>? MlfBOFghcA>? NVeyZY1OTE2VTx?= Ml;kbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NHq3O5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
ACHN NVXObJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG4OUDPxE1? MkfnOFghcA>? M3\mdWROW09? NXXOb4NucW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MkH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
115 MnnxSpVv[3Srb36gRZN{[Xl? M2HRZlAvPS9zL{Wg{txO NXjiTGQ4PDhiaB?= NVvQO|NKTE2VTx?= M{jr[Ixm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MmfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
A498 NFzKUldHfW6ldHnvckBCe3OjeR?= NVnXVmxDOC53L{GvOUDPxE1? MoLZOFghcA>? NUHlR2lGTE2VTx?= MWTs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
Caki-2 NHvRbHBHfW6ldHnvckBCe3OjeR?= Mk\FNE42NzFxNTFOwG0> NH74eHU1QCCq Mle2SG1UVw>? NWDjO2ZCdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= NXv5WY1IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
ACHN NGrSWI9HfW6ldHnvckBCe3OjeR?= MlvmNE42NzFxNTFOwG0> MXy0PEBp M4Doe2ROW09? MYns[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NYCweXp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
117 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYjQcmxCOC53LUGwJO69VQ>? NWixNFAxOC14IHS= Mn7PSG1UVw>? M1fpb4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYm5O|ZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
115 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkS2NE42NTFyIN88US=> NFjKTJgxNTZiZB?= MVrEUXNQ MWnpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
A498 MkTLR4VtdCCYaXHibYxqfHliQYPzZZk> M3HxWFAvPS1zMDFOwG0> NX36O25EOC14IHS= MYTEUXNQ MVvpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIjFe3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
Caki-2 NEK3U2dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2fJeFAvPS1zMDFOwG0> MUOwMVYh\A>? MWrEUXNQ MlXkbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGi2enA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
ACHN NFjiOGxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWCwMlUuOTBizszN MojWNE03KGR? NF3le|BFVVOR NFvKOodqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
MCF7  NH3ifnZHfW6ldHnvckBCe3OjeR?= NEjnSWwzNjViwsXN MU[0PEBp MoD5SG1UVw>? MoXV[IVkemWjc3XzJJRp\SCqb33vcI9od3W|IFTTRkBz\XCjaYKg[pJmeXWnbnPp[ZM> NVfISpB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFU6ODJpPkK1NFg2QTB{PD;hQi=>
MCF7  NVzTfJB3S2WubDDWbYFjcWyrdImgRZN{[Xl? Mom2Nk42KML3TR?= MYW1JIQ> NGXicm1FVVOR MoW5d4Vve2m2aYrld{BOS0Z5IITvJHBCWlBiaX7obYJqfGmxbh?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB6NUmwNkc,OjVyOEW5NFI9N2F-
RAW 264.7 MmnPSpVv[3Srb36gRZN{[Xl? MnjaNVDDqM7:TR?= MV2zNEBucW5? MmXmbY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMg M3H6e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOVQ4Lz5{NUG3NlU1PzxxYU6=
RAW 264.7 NY[wRZhETnWwY4Tpc44hSXO|YYm= NEfubG0yOMLizszN NUnOPFJTOzBibXnu M376OpJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= NHLIN4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3NlU1Pyd-MkWxO|I2PDd:L3G+
RAW 264.7 NFK2Sm5HfW6ldHnvckBCe3OjeR?= NGjJcWEyOMLizszN NYTLNlBpOzBibXnu MVLwdoV3\W62czD0bIUheDV|IILl[JVkfGmxbjDpckBz\XOyb37z[UB1dyCOUGO= M1fSVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOVQ4Lz5{NUG3NlU1PzxxYU6=
SUM102PT MV7GeY5kfGmxbjDBd5NigQ>? M2fhclExyqEQvF2= MkK3NlQhcA>? M2DINWROW09? NXzmXlRJcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u Mn3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe3NlkoRjJ3MkW3O|I6RC:jPh?=
SK-BR-7 M4XEPGZ2dmO2aX;uJGF{e2G7 MWWxNOKh|ryP MV[yOEBp NUjBOJFkTE2VTx?= NXnr[YVqcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u MlLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe3NlkoRjJ3MkW3O|I6RC:jPh?=
MCF-10CA1a Mmn2SpVv[3Srb36gRZN{[Xl? MYGxNOKh|ryP NXLnbGFxOjRiaB?= MUXEUXNQ MnSwbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M2X4dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkW3O|I6Lz5{NUK1O|czQTxxYU6=
MCF-10CA1a MonoSpVv[3Srb36gRZN{[Xl? NF65VHkyOMLizszN NInsVFIzPCCq NVHCZo04TE2VTx?= NELDTW1l\WO{ZXHz[ZMhfGinIGTHSk3PujNvaX7keYNm\CCvUl7BJIxmfmWuczDv[m1OWDJuwrDNUXA6NCCjbnVCpIlvfGWpcnnuxsDPusLiMx?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3N{eyPUc,OjV{NUe3Nlk9N2F-
MCF-10A1  MkHtSpVv[3Srb36gRZN{[Xl? M3WzdVExyqEQvF2= NWmzSFR6OjRxNEigbC=> NW\W[oMzTE2VTx?= NU\qVId5cW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3N{eyPUc,OjV{NUe3Nlk9N2F-
MCF-10CA1a MmT6SpVv[3Srb36gRZN{[Xl? NVy3bXNHOTEEoN88US=> MXu0PEBp M4eyUGROW09? M1PVRYlvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? NG[xOpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK1O|czQSd-MkWyOVc4Ojl:L3G+
HCT116  MVnGeY5kfGmxbjDBd5NigQ>? MVexNEDDvU1? Ml6yNlQhcA>? NIXXOJlk[XW|ZYOgZUBxPTNvZHXw[Y5l\W62IITleJJieGyxaXSgS|Eu[XK{ZYP0JIlvKGSrcHzvbYQhUEOWMUG2JINtd26nczDEN{BidmRiREi= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6MEC1OUc,OjV|OECwOVU9N2F-
A2780 M3;LXGZ2dmO2aX;uJGF{e2G7 MUGxNOKh|ryP MnrLNlFpyqB? MWTEUXNQ NFnXb4Vl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> NWm4UGxlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlY2PDhpPkK1OFI3PTR6PD;hQi=>
NCI-H23 M2W1SWZ2dmO2aX;uJGF{e2G7 NFflcG4yOMLizszN NGH1N4UzOWkEoB?= MUHEUXNQ MlnR[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= NIPSTJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOlU1QCd-MkW0NlY2PDh:L3G+
A2780 MkfOSpVv[3Srb36gRZN{[Xl? NUjKU5I3OTEEoN88US=> M3LzRVIycMLi NE\VS2tFVVOR NITyboFqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2Mk[1OFgoRjJ3NEK2OVQ5RC:jPh?=
NCI-H23 NE\hSFJHfW6ldHnvckBCe3OjeR?= NWnhS4RkOTEEoN88US=> M1TQO|IycMLi M4S3fmROW09? NV3qdYFMcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{NkW0PEc,OjV2Mk[1OFg9N2F-
OVCAR10 M{W2[GZ2dmO2aX;uJGF{e2G7 NYHmXI9{OTEEoN88US=> MkKxNlFpyqB? NGrZcHlFVVOR NUj5[HhbcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{NkW0PEc,OjV2Mk[1OFg9N2F-
MCF-7 NUTYO3FrTnWwY4Tpc44hSXO|YYm= NEPKc|MyOMLizszN NHL3c|ExNTJ2IHi= NH7Rem9qdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= MlTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEKzO|MoRjJ3NEiyN|c{RC:jPh?=
SMMC-7721 NXzEe4tMTnWwY4Tpc44hSXO|YYm= MX2xNEDPxE1? NWDhSYw4OzZiaB?= MVHEUXNQ M1:0eYNifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3 NH7ESok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0OFM3OSd-MkW1OFQ{PjF:L3G+
SMMC-7721 MmrSSpVv[3Srb36gRZN{[Xl? NGqwfWMyOCEQvF2= MonIOFghcA>? NFuzWFVFVVOR MmrrbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> M3rMUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUS0N|YyLz5{NUW0OFM3OTxxYU6=
SMMC-7721 MoHISpVv[3Srb36gRZN{[Xl? MnT5NVAh|ryP M1[3O|Q5KGh? NYHFNZp3TE2VTx?= NWnsc3R7cW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>? NFriVHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0OFM3OSd-MkW1OFQ{PjF:L3G+
SMMC-7721 NXPUO|hzTnWwY4Tpc44hSXO|YYm= M1\EZVExKM7:TR?= MWm0PEBp NH7v[nRFVVOR MVTjZZV{\XNiRF7BJGRUSiCmYX3h[4U> NFzEO409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0OFM3OSd-MkW1OFQ{PjF:L3G+
DU4475  MUXGeY5kfGmxbjDBd5NigQ>? MoL3OU8yOC9{MDFOwG0> MVKyOOKhcA>? NIHjcFNld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 NFiw[Xo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0O|E4PCd-MkW1OFcyPzR:L3G+
MCF-7  MX\GeY5kfGmxbjDBd5NigQ>? NVz4NmNoOTEEoN88US=> M33ld2ROW09? M1rQTolvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>? NVu4[5BlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFI4ODNpPkK1O|AzPzB|PD;hQi=>
C2C12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLHNVDDqM7:TdMg NXjnUYh5OjRxNEivO|IhcA>? NX7vTnp2TE2VTx?= NF[0VpFqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? NXP6ZYQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O|E4QTRpPkK1PFcyPzl2PD;hQi=>
L6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvlNVDDqM7:TdMg M33RdFI1NzR6L{eyJIg> Mn7iSG1UVw>? NX\ycIxncW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w NF3jSlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3NVc6PCd-MkW4O|E4QTR:L3G+
CRL-5908 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\xNlQhcA>? M4\LTGlEPTB;M{iuO|EhyrFiMj60N{DPxE1? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUKzNEc,OjZzMkWyN|A9N2F-
A549-920 M1HkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO4dFBZOjRiaB?= NUDMTphrUUN3ME2zN{45PSEEsTC0Mlg1KM7:TR?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUKzNEc,OjZzMkWyN|A9N2F-
A549-NTC NYHT[nYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jXclI1KGh? Mn\2TWM2OD1zOT60NkDDuSBzLkm2JO69VQ>? NH;DNIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOVI{OCd-Mk[xNlUzOzB:L3G+
A549 M3H2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzJNlQhcA>? NGDId5NKSzVyPUG3MlY5KMLzIESuOVIh|ryP MoXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkWyN|AoRjJ4MUK1NlMxRC:jPh?=
C666-1 MkL0RZBweHSxc3nzJGF{e2G7 MYqxNEDDvU1? MXm0PE84OiCq MmTOSG1UVw>? MXvz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= M4LNd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkWyOVc2Lz5{NkK1NlU4PTxxYU6=
C666-1  Mlu1SpVv[3Srb36gRZN{[Xl? MmXFNVAhyrWP MlHINlQhcA>? MV3EUXNQ M3;ZOYFkfGm4YYTld{B1cGVicEWzJJBifGi5YYmsJJVxemWpdXzheIlv\yCyNUOsJJAzOSCjbnSgUYRuOg>? MoSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUK1O|UoRjJ4MkWyOVc2RC:jPh?=
C666-1 MonvR4VtdCCYaXHibYxqfHliQYPzZZk> NHTNV|YyOCEEtV2= M2DqS|Q5KGh? MmPoSG1UVw>? MkTad4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw NUG5NY1mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
C666-1 MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLCOmxuUUN3ME2xPU46PcLzOD65N{DPxE1? Ml33QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUK1O|UoRjJ4MkWyOVc2RC:jPh?=
NP460 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y5SWlEPTB;MkKuPFXDuTFwMUig{txO M2fNflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkWyOVc2Lz5{NkK1NlU4PTxxYU6=
NP69 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTNzLk[5xtEzNjV2IN88US=> NVzhVHJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
MCF7 M4j3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f3eFXDqM7:TR?= NWrJPYNNPDkEoHi= MkjYZoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ M1zXN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WwOVY2Lz5{NkO1NFU3PTxxYU6=
HuH-7 NX3HRZlSTnWwY4Tpc44hSXO|YYm= NW\UUFRwOTBizszN MnzpN|YhcA>? M3TicWROW09? NILVe25ld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? NYSzZnZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPFY{OTJpPkK0Nlg3OzF{PD;hQi=>
AT2 M2e0PWZ2dmO2aX;uJGF{e2G7 NVnEPWJSPS9zMDFOwG0> NV3kTJBidGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= NXfpcoZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFAzODNpPkK0NlQxOjB|PD;hQi=>
REH NYPE[4FtTnWwY4Tpc44hSXO|YYm= MXy1M|ExKM7:TR?= MoK0cIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2MEKwN{c,OjR{NECyNFM9N2F-
UoCB6 MlzrSpVv[3Srb36gRZN{[Xl? NULIV3ZVPS9zMDFOwG0> M1;me4xm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li M1y3NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkSwNlA{Lz5{NEK0NFIxOzxxYU6=
AT2 NVLsNplJS2WubDDWbYFjcWyrdImgRZN{[Xl? NIDjd2sxNTJ3IN88US=> MkDNbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MlH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NECyNFMoRjJ2MkSwNlA{RC:jPh?=
REH MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4TUZ|AuOjVizszN MnizbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NEL4dIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0NFIxOyd-MkSyOFAzODN:L3G+
UoCB6 MljaR4VtdCCYaXHibYxqfHliQYPzZZk> Mo[xNE0zPSEQvF2= MnvLbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M4niVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkSwNlA{Lz5{NEK0NFIxOzxxYU6=
A2780 M3jDW2Z2dmO2aX;uJGF{e2G7 MVu1M|ExNzJyIN88US=> NWHGZYpLOjRiaB?= MWf1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? MnrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{[xOFcoRjJ2MUO2NVQ4RC:jPh?=
H460 MmPlSpVv[3Srb36gRZN{[Xl? NYr6fFZSPS9zMD:yNEDPxE1? NW\OS3BLOjRiaB?= MkjyeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NF\wfng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOlE1Pyd-MkSxN|YyPDd:L3G+
Lovo  NVHUV|RbTnWwY4Tpc44hSXO|YYm= M{LJSlUwOTBxMkCg{txO NWHZRlE1OjRiaB?= NX73eVhrfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF|NkG0O{c,OjRzM{[xOFc9N2F-
A2780 NHnrWpVCeG:ydH;zbZMhSXO|YYm= NY\JUYROPS9zMD:yNEDPxE1? M4Dt[VI1KGh? M{\ieIVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN NHPyU3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOlE1Pyd-MkSxN|YyPDd:L3G+
H460 M3XPTWFxd3C2b4Ppd{BCe3OjeR?= Mnm3OU8yOC9{MDFOwG0> M3PXNVI1KGh? M1vD[4VvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MkLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{[xOFcoRjJ2MUO2NVQ4RC:jPh?=
Lovo  M3PEWWFxd3C2b4Ppd{BCe3OjeR?= M4j3TlUwOTBxMkCg{txO MYCyOEBp M2\SUIVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN M1jaWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO2NVQ4Lz5{NEGzOlE1PzxxYU6=
U87MG MX3GeY5kfGmxbjDhd5NigQ>? M3K0OFExKG2rboO= M1u3RmJqdmSrbnegZYZncW6rdImgeI8hVUSPMjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJG1FVTJxcEWzJJBzd3SnaX6gbY51\XKjY4Tpc44h[W[2ZYKgNVAhdWmwczDifUByfWGwdHn0ZZRqfmVic3Hu[Jdq[2hiaX3teY5wKGG|c3H5MEBKSzVyIE2gNE4yODR3IN88UU4> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB3MEe4Nkc,OjdyNUC3PFI9N2F-
U87MG MYrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3fsNlQ5KGi{cx?= MnfrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXOEfNS{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBxPTNiYX\0[ZIhPDhiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDZwNTFOwG0v MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB3MEe4Nkc,OjdyNUC3PFI9N2F-
U343MG NFnqcmpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3LlRVQ5KGi{cx?= NEDzbHdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGWzOFNOTyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCyNUOgZYZ1\XJiNEigbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEGyMlYh|ryPLh?= NXjUR25wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOVA4QDJpPkK3NFUxPzh{PD;hQi=>
SW620 MnnzR5l1d3SxeHnjbZR6KGG|c3H5 NHT6[2k4OiCqcoO= MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOCClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyIE2gNE4{QCEQvF2u MlHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVkyOzN2Lze+R4hGVUKOPD;hQi=>
A549 M2LH[GN6fG:2b4jpZ4l1gSCjc4PhfS=> MUW3NkBpenN? MmHoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyIE2gNE41OSEQvF2u NEfCWHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQTF|M{SvK|5EcEWPQly8M4E,
SJSA1 MWrDfZRwfG:6aXPpeJkh[XO|YYm= NIT1UnQ4OiCqcoO= MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTnNCOSClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyIE2gNU45OSEQvF2u NFW5ZZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQTF|M{SvK|5EcEWPQly8M4E,
HCT116 M1rTb2N6fG:2b4jpZ4l1gSCjc4PhfS=> MojTO|IhcHK| NH3KWIZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDRwNkOg{txONg>? NXX5S5djRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTlzM{O0M{c,S2iHTVLMQE9iRg>?
PC3 M3K1RmN6fG:2b4jpZ4l1gSCjc4PhfS=> M4PHe|czKGi{cx?= NGHNcGNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFYvOzdizszNMi=> NFnS[VM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQTF|M{SvK|5EcEWPQly8M4E,

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
MDM2 / p53 / ALKBH2 / p21 / PUMA; 

PubMed: 23258843     


CCF-STTG1 cells were treated with the MDM2 antagonist nutlin-3 (0–8 µM) for 24h before cell lysates were collected for western blotting.

RRM1 / RRM2 / p53R2 / p21 / p53 / pS6 / S6; 

PubMed: 28507282     


(A) Rh18 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. (B) Rh30 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. GAPDH and Actin served as loading controls.

23258843 28507282
Immunofluorescence
Lamin A / Lamin C / p16 / H3K9me3; 

PubMed: 30728349     


c Immunofluorescence images of nuclear deformation and p16 expression after Nutlin-3 treatment for different time period. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were subjected to immunofluorescence staining for Lamin A/C (Red), p16 (Green), and counterstained with DAPI (Blue). dImmunofluorescence images of nuclear deformation and decreased expression of H3K9me3 in HCT p53+/− cells (left). Counting of histone H3K9me3-positive cells (middle) and signal intensities (right) on the basis of IF staining. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were IF stained with Lamin A/C (Red), H3K9me3 (Green), and counterstained with DAPI (Blue). *P < 0.05. 

Merlin / cyclin D1 / p53 / MDM2; 

PubMed: 30274821     


The changes in the subcellular localization of proteins in response to Nutlin-3. Nuclear merlin was indicated with white arrows. Scale bar = 50 μm.

p53; 

PubMed: 24286312     


The subcellular localization of p53 was detected under immunofluorescence microscope (1,000×). The cells were treated as indicated and stained for p53 (red). Nuclei were counterstained with DAPI (blue).

30728349 30274821 24286312
Growth inhibition assay
Cell viability; 

PubMed: 29286113     


Inhibitory effect of nutlin-3 for the cell proliferation after cultivate cells at different concentration for three times (24, 48 and 72 h), respectively.

29286113
体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作（参考用のみ）

キナーゼ試験：

[1]
- 合併

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験：

[1]
- 合併
  • 細胞株： HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度： Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間： 8, 24, and 48 hours
  • 実験の流れ：

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験：

[1]
- 合併
  • 動物モデル： Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 投薬量： 200 mg/kg
  • 投与方法： Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4
CAS No. 890090-75-2
Storage powder
in solvent
別名 N/A
Smiles CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）
投与量 mg/kg 動物平均体重 g 投与体積（動物毎） ul 動物数 匹
ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答：

    It is a racemate.

selleck catalog

Mdm2シグナル伝達経路

相関Mdm2製品

  • Idasanutlin (RG-7388)

    Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • NSC 207895

    NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

  • Nutlin-3a

    Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.

    Features:Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

  • Nutlin-3b

    Nutlin-3b ((+)-Nutlin-3) is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.

  • Z-VAD-FMK

    Z-VAD-FMK (Z-VAD(OMe)-FMK) is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • Navitoclax (ABT-263)

    Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID